Get the Stockscreener App
276.08
0.10%
0.27
Pre-market:
275.55
-0.53
-0.19%
Insulet Corporation stock is traded at $276.08, with a volume of 588.26K.
It is up +0.10% in the last 24 hours and up +3.57% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
See More
Previous Close:
$275.81
Open:
$279.02
24h Volume:
588.26K
Relative Volume:
1.11
Market Cap:
$19.37B
Revenue:
$1.98B
Net Income/Loss:
$420.90M
P/E Ratio:
47.27
EPS:
5.84
Net Cash Flow:
$218.20M
1W Performance:
+3.39%
1M Performance:
+3.57%
6M Performance:
+41.56%
1Y Performance:
+35.03%
1-Day Range:
$275.87
$282.86
1-Week Range:
$263.13
$282.86
52-Week Range:
$160.19
$282.86
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
276.08 | 19.37B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
Insulet (NASDAQ:PODD) Hits New 52-Week HighTime to Buy? - MarketBeat
Insulet stock hits 52-week high at $281.99 amid robust growth - Investing.com
Insulet Co. (NASDAQ:PODD) Shares Sold by AMI Asset Management Corp - MarketBeat
Sax Wealth Advisors LLC Acquires 1,532 Shares of Insulet Co. (NASDAQ:PODD) - MarketBeat
6,742 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Avanza Fonder AB - MarketBeat
(PODD) Investment Analysis - Stock Traders Daily
Assenagon Asset Management S.A. Has $27.25 Million Stock Holdings in Insulet Co. (NASDAQ:PODD) - MarketBeat
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
GEHC or PODD: Which Is the Better Value Stock Right Now? - Yahoo Finance
Contravisory Investment Management Inc. Takes $552,000 Position in Insulet Co. (NASDAQ:PODD) - MarketBeat
USA Financial Formulas Makes New Investment in Insulet Co. (NASDAQ:PODD) - MarketBeat
PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU - Yahoo Finance
Insulet Co. (NASDAQ:PODD) Shares Purchased by Ayrshire Capital Management LLC - MarketBeat
Insulet rolls out Omnipod 5 in more European countries - Mass Device
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe - Business Wire
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 - Marketscreener.com
What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing? - Simply Wall St
Insulet Co. (NASDAQ:PODD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Is Insulet Stock Outperforming the Dow? - MSN
Insulet Sets Q4 2024 Earnings Date: Omnipod 5 Maker to Report Financial Results February 20 - StockTitan
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
What Does Insulet Corporation's (NASDAQ:PODD) Share Price Indicate? - Yahoo Finance
(PODD) On The My Stocks Page - Stock Traders Daily
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Insulet stock supported by Buy rating as analyst notes US type 2 label - Investing.com Canada
Insulet (NASDAQ:PODD) Price Target Raised to $324.00 - MarketBeat
Insulet Corporation (PODD) PT Raised to $324 at TD Cowen - StreetInsider.com
Those who invested in Insulet (NASDAQ:PODD) five years ago are up 49% - Simply Wall St
GEHC vs. PODD: Which Stock Is the Better Value Option? - Yahoo Finance
Insulet price target raised to $300 from $270 at BTIG - Yahoo Finance
Insulet Corporation (PODD) PT Raised to $300 at BTIG - StreetInsider.com
BTIG maintains Buy on Insulet stock, adjusting projections for Omnipod and EBIT margins - Investing.com Nigeria
Is Insulet Stock Outperforming The Dow? - Barchart
Heavy Interest in Insulet’s Insulin Delivery Device - Yahoo Finance
Principal Financial Group Inc. Grows Position in Insulet Co. (NASDAQ:PODD) - MarketBeat
How to Take Advantage of moves in (PODD) - Stock Traders Daily
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
Massachusetts Jury Sets New Record Under Federal Defend Trade Secrets Act With $452 Million Damages Award - JD Supra
Insulin Pump Market Valuation to Jump to Reach US$ 25.40 Billion by 2033 | India and China Offering Lucrative Growth Opportunities Says Astute Analytica - GlobeNewswire Inc.
The Most Significant Trade Secrets Cases Of 2024 - Law360
Executive VP Of Insulet Sold 26% Of Their Shares - Simply Wall St
Insulet Co. (NASDAQ:PODD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Here's Why Insulet (NASDAQ:PODD) Can Manage Its Debt Responsibly - Simply Wall St
Insulet corp EVP Benjamin Eric sells $1.17 million in shares - Investing.com India
Insulet corp EVP Benjamin Eric sells $1.17 million in shares By Investing.com - Investing.com Australia
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today - Benzinga
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):